This week’s clinical update focuses on a newly posted Phase 1 clinical trial for a CRISPR-edited CAR-T therapy for relapsed or refractory CD19+...

In this week’s clinical update, we take a look at a CRISPR-engineered T cell receptor-T cell therapy that is designed to treat all genetic subtypes of...

This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

This week’s clinical update looks at a Phase 1/2 trial for a CRISPR-edited checkpoint cell therapy for difficult-to-treat gastrointestinal cancers...

This week’s clinical update looks at a Phase 1/2 trial for VOR33, a CRISPR-Cas9-edited haematopoietic stem and progenitor cell (HSPC) therapy under...

Two weeks ago, we hosted a CMN webinar on CRISPR Delivery Systems. Several hundred attendees from all continents tuned in for the live event. Here's a...

This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...